A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
Open Access
- 14 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 11 (1), 1-7
- https://doi.org/10.1038/s41467-020-17972-1
Abstract
The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.This publication has 21 references indexed in Scilit:
- Live attenuated influenza vaccine use and safety in children and adults with asthmaAnnals of Allergy, Asthma & Immunology, 2017
- Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trialThe Lancet. Global Health, 2017
- Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet, 2016
- Vaccine-generated lung tissue–resident memory T cells provide heterosubtypic protection to influenza infectionJCI Insight, 2016
- Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trialThe Lancet, 2015
- Respiratory Virus VaccinesPublished by Elsevier BV ,2015
- Safety of live attenuated influenza vaccine in atopic children with egg allergyJournal of Allergy and Clinical Immunology, 2015
- A Single Sublingual Dose of an Adenovirus-Based Vaccine Protects against Lethal Ebola Challenge in Mice and Guinea PigsMolecular Pharmaceutics, 2011
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in MicePLOS ONE, 2008